Oren Gilad
Principal investigator, leads APREA THERAPEUTICS, INC..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2023First federal award
$2.0MFederal grants as PI2 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
2 awards · $2.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Feb 5, 2024 | NIH | SBIR Phase II Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer | $1.1M | APREA THERAPEUTICS, INC. |
| Feb 13, 2023 | NIH | SBIR Phase II Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer | $862K | APREA THERAPEUTICS, INC. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#1,044
Awards as PI#1,252
Patents#273
Companies
- APREA THERAPEUTICS, INC.Leads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.